ARVO/Alcon Keynote Series

Print

ARVO/Alcon Keynote Series

The 2019 opening and closing ARVO/Alcon Keynote Lectures will provide Annual Meeting attendees a chance to dig deep into elements of the meeting theme, From Bench to Bedside and Back, to hear about how scientists are working to better understand genetics in order to address serious and devastating diseases that impact the eye and vision. 

Opening Keynote: Sunday, April 28, 2019

How cells export proteins and RNA - applications to the treatment of disease

Randy Schekman

Randy W. Schekman, PhD
Nobel Laureate (Physiology or Medicine, 2013)
Investigator, Howard Hughes Medical Institute
Professor of cell and developmental biology, Department of Molecular and Cell Biology, University of California at Berkeley

Adjunct professor of biochemistry and biophysics, University of California, San Francisco

Dr. Schekman has studied how cells transport proteins from their site of synthesis in the endoplasmic reticulum to their various ultimate destinations inside or outside the cell, using membrane vesicles as a vehicle. His research has involved yeast as a model organism.  Additionally, Dr. Schekman’s work has harnessed the power of yeast genetics to understand this fundamental biological process of intracellular vesicular trafficking. 

 

Closing Keynote: Thursday, May 2, 2019

Models of translational science to span innovation gaps in academia

Martin Gleave

Martin Gleave, CM, MD, FRCSC, FACS
Director, The Vancouver Prostate Centre
Liber Ero British Columbia Leadership Chair in Prostate Research
Distinguished professor and vice-chair, Department of Urological Sciences, University of British Columbia, Vancouver

Dr. Gleave’s research demonstrates how science can successfully move from the lab bench to a therapeutic intervention for patients. His studies have centered around characterizing the molecular mechanisms that mediate treatment resistance in cancer, focusing on stress-activated adaptive responses that drive acquired treatment resistance and designing rational combination co-targeting strategies to abrogate the stress response to create conditional lethality and improve cancer control. He has patented several anti-cancer drugs and, in 2001, founded OncoGenex Technologies, for which he serves as chief scientific officer.